48
Repurposing Brewery Infrastructure for Protein
The economic logic driving Pacifico Biolabs is a pragmatic response to a shifting European consumer market. As alcohol consumption declines across the continent, many regional breweries are facing the reality of underutilized capacity. Rather than allowing these fermentation tanks to sit idle, the startup is transforming them into the production hubs of the future.
This strategy bypasses the most expensive hurdle in the alternative protein sector: the massive capital expenditure required to build specialized bioreactors and new facilities. By integrating into existing industrial infrastructure, the company eliminates long design and construction cycles.
It is a lean approach to scaling. Instead of betting on a single, massive “mega-factory,” the model relies on a distributed network of existing assets. This allows for faster expansion and a significantly lower risk profile for investors.
“We are not just creating a food ingredients company. We are employing Europe’s industrial infrastructure for the food of the future.”
Zac Austin, Co-founder and CEO of Pacifico Biolabs
Breaking the Texture and Price Barrier
Alternative proteins have historically struggled with three primary obstacles: price, texture, and nutritional value. Most plant-based options rely heavily on additives to mimic the “mouthfeel” of meat, which often compromises the clean-label appeal for health-conscious consumers.
Mycelium fermentation offers a biological shortcut. Because fermented mycelium naturally possesses a structure similar to meat and a neutral flavor profile, it requires fewer additives. This allows food manufacturers to create private-label products more efficiently.
The real victory, however, is in the pricing. By slashing the overhead costs associated with factory construction, the company is focusing on reaching price parity with traditional meat. This is the only way alternative proteins move from a niche luxury to a mass-market staple.
Expansion Targets and the 2026 Retail Timeline
The €7 million injection, supported by several venture capital funds and a regional brewery partner, provides the runway needed for an aggressive expansion. The company is centering its production base in Saxony and is currently expanding its team in Leipzig.
The roadmap for the next 18 months focuses on three specific goals:
Scaling production capacity to reach 200 tons per month.
Formalizing partnerships with food manufacturers to integrate mycelium proteins into existing product lines.
Preparing for commercial launches in Germany, Austria, Switzerland, and Northern European markets.
According to reporting by Laikas, the company expects its products to hit retail shelves via brand and retailer partners by the end of 2026.
The success of this model depends on the continued willingness of breweries to pivot their business models. If Pacifico Biolabs can prove that “protein breweries” are more profitable than traditional beer production, it could trigger a wider industrial shift across Europe’s agricultural and manufacturing sectors.
Berlin-based Pacifico Biolabs closed a €7 million Series A funding round to scale its mycelium fermentation protein production to 200 tons per month. Founded in 2022, the company plans to utilize underused brewery fermentation tanks across Germany, Austria, Switzerland, and Northern Europe, targeting a retail debut by the end of 2026.
